ArticlemBio2020
Outer Membrane Disruption Overcomes Intrinsic, Acquired, and Spontaneous Antibiotic Resistance.
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 98 citations in OpenAlex.
- Article
- Herbal extracts as antibiotic adjuvants against ESKAPE pathogens: mechanisms and therapeutic potential.Engineering microbiology · 2026Review
- Genome-guided antimicrobial potential of Bacillus stercoris from coastal sand with activity against multidrug-resistant bacteria, including MRSA.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Leveraging the lipoprotein trafficking pathway for the development of novel antimicrobials.RSC chemical biology · 2026Review
- NV716 acts as an envelope-active adjuvant that enhances antibiotic accumulation in Pseudomonas aeruginosa.npj antimicrobials and resistance · 2026Article
- Overcoming prokaryotic toxicity: a SUMO-fused secretory platform in Komagataella phaffii for high-yield production of phage holin Hol41.Microbial cell factories · 2026Article
- Recombinant NK1 Protein and LEDs: An Innovative Strategy to Counteract Resistant Staphylococcus pseudintermedius and Pseudomonas aeruginosa Strains.Probiotics and antimicrobial proteins · 2026Article
- Bacterial cell envelope-targeting antibiotics.Nature reviews. Microbiology · 2026Review
- First report on the biological characteristics of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Phage resistance of Bordetella avium due to an altered cell wall results in increased susceptibility to the polypeptide antibiotics colistin and polymyxin B.Scientific reports · 2025Article
- Marine-derived new peptaibols with antibacterial activities by targeting bacterial membrane phospholipids.Acta pharmaceutica Sinica. B · 2025Article
- Novel Antibacterial Approaches and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Metabolic state-driven nutrient-based approach to combat bacterial antibiotic resistance.npj antimicrobials and resistance · 2025Review
- Large-scale combination screens reveal small-molecule sensitization of antibiotic-resistant gram-negative ESKAPE pathogens.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- 6-Bromoindole- and 6-Bromoindazole-Based Inhibitors of Bacterial Cystathionine γ-Lyase Containing 3-Aminothiophene-2-Carboxylate Moiety.Molecules (Basel, Switzerland) · 2025Article
- Overexpression of the major facilitator superfamily efflux pump geneFrontiers in cellular and infection microbiology · 2025Article
- Antimicrobial peptides and proteins against drug-resistant pathogens.Cell surface (Amsterdam, Netherlands) · 2024Review
- Synergistic combinations of novel polymyxins and rifampicin with improved eradication of colistin-resistantBiofilm · 2024Article
- Guanethidine Enhances the Antibacterial Activity of Rifampicin Against Multidrug-Resistant Bacteria.Microorganisms · 2024Article
- A screen for cell envelope stress uncovers an inhibitor of prolipoprotein diacylglyceryl transferase, Lgt, iniScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Disruption of the outer membrane (OM) barrier allows for the entry of otherwise inactive antimicrobials into Gram-negative pathogens. Numerous efforts to implement this approach have identified a large number of OM perturbants that sensitize Gram-negative bacteria to many clinically available Gram-positive active antibiotics. However, there is a dearth of investigation into the strengths and limitations of this therapeutic strategy, with an overwhelming focus on characterization of individual potentiator molecules. Herein, we look to explore the utility of exploiting OM perturbation to sensitize Gram-negative pathogens to otherwise inactive antimicrobials. We identify the ability of OM disruption to change the rules of Gram-negative entry, overcome preexisting and spontaneous resistance, and impact biofilm formation. Disruption of the OM expands the threshold of hydrophobicity compatible with Gram-negative activity to include hydrophobic molecules. We demonstrate that while resistance to Gram-positive active antibiotics is surprisingly common in Gram-negative pathogens, OM perturbation overcomes many antibiotic inactivation determinants. Further, we find that OM perturbation reduces the rate of spontaneous resistance to rifampicin and impairs biofilm formation. Together, these data suggest that OM disruption overcomes many of the traditional hurdles encountered during antibiotic treatment and is a high priority approach for further development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.